Nov 5, 2023, 18:42
A strategic collaboration with Jiangsu Hengrui Pharmaceuticals and EMD Serono
EMD Serono posted on LinkedIn.
“News: Today we entered a strategic collaboration with Jiangsu Hengrui Pharmaceuticals. This agreement aims to strengthen our robust internal oncology pipeline in DNA damage response (DDR) inhibition and antibody-drug conjugates (ADC) to deliver on our ambition to advance therapeutic options for patients with difficult-to-treat cancers. Learn more here.”
Source: EMD Serono/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 17:45
Nov 20, 2024, 17:40
Nov 20, 2024, 17:35
Nov 20, 2024, 17:29
Nov 20, 2024, 17:24
Nov 20, 2024, 16:38
Nov 20, 2024, 16:24